ABcann Global (TSX.V: ABCN) Begins Trading May 4th.
The next major marijuana success story has hit the markets.
It’s a mid-size marijuana grower that’s on it’s way to major success.
It’s already implementing one of the largest expansions in the world right now.
It’s been working away at creating the most cost-effective and highest-quality indoor marijuana farming techniques and it’s already producing marijuana at twice the rate of its top competitors.
It’s earned the backing of pharmaceutical executives, renowned marijuana scientists, and top agriculture experts.
It’s still trading for a less than it’s competitors did BEFORE their shares went on to rise more than 711% and 887%.
And it’s going to be available to new investors now.
The company is ABcann Global (TSX.V ABCN) and if you’re looking for the next big marijuana story, this is it.
#1 Marijuana Stock For 2017
On May 4th, 2017, ABcann (TSX.V ABCN) will become available to public investors.
The company joined a handful of select, government-backed marijuana growers which have been soaring higher.
After it becomes open to public ABcann will officially join the likes of:
Canopy Growth ( TWMJF / WEED.cn ) which ran 711% from its IPO.
Aphria Inc (APHQF / APH.cn) is another one. It has ran up 938% since it hit the public markets.
Aurora Cannabis (ACBFF / ACB.cn) climbed 887% after its IPO.
SupremePharma (SPRWF / SL.cn) has soared 1364% from its IPO.[AM1]
ABcann (TSX.v ABCN) is the NEXT one of those.It has the very real potential to run up as much as 1364% just like the other Canadian marijuana growers.
However, as you’ll see today, it could blow them all away in a matter of months.
ABCann could becoime the world’s first global marijuana powerhouse...
ABcann (TSX.V ABCN) has everything going for it to make it a standout success.
1. ABcann’s path to growth is protected by the Government!
Since 2013, more than 1,600 companies have applied to Health Canada to become a licensed producer (LP) of medical marijuana.
Only 5 companies won coveted LP status in 2013, just another 14 made the cut in 2014.
Getting an official license is like winning the lottery for marijuana companies in Canada.
And you remember already saw how they rose 711%, 887%, and 938%, and as much as 1364%.
ABcann has its license too and has now joined that exclusive group.
However, ABcann was one of the first companies to do get the license and has been parlayed its “head start” into something none of these companies have achieved.
2. ABcann is a marijuana technology powerhouse— It's about Production per square foot.
Here’s where ABcann stands out among Canada’s licensed marijuana producers—technology.
Yes, it’s a low-cost producer like Aphria.
Yes, it’s a high-quality producer like Tweed (Canopy).
But its competence is unique!
ABcann can grow every one or its 14 MMJ strains to exact specifications for precise THC and cannabidiol (CBD) balances.
Every plant, every time.
And it can scale up to infinity. ABcann can replicate its proprietary growing system for any MJ strain anywhere.
3. Barriers to entry are too high for mass competition—
Canada’s not like the “Wild West” system in some US states like Colorado where almost anyone can get in the business somehow.
Canada’s marijuana growers enjoy the next best thing to no competition! It’s that hard to break in.
Since 2013, Health Canada (think Canada's FDA) has approved less than 2% of applications to grow marijuana commercially.
PIC (of an official diploma or licens-y looking thing with a raised gold seal?)
4. Ramping up production 2017
ABcann has laid out a plan to rapidly expand production.
Now, ABcann is no start-up marijuana company. It already has a 14,500 square foot growth facility in Ontario, Canada.
This is where it already achieved its industry-leading production 250 grams of marketable marijuana per square foot (more than double the average among Canadian marijuana producers).
The reason it’s going public is to raise another C$23 million to get started on the next major expansion project.
This project is expected to add an additional 71,000 square feet to ABcann’s total marijuana footprint.
After completed, the massive expansion combined with ABcann’s market-leading production methods will put it on par with Canadian marijuana producers valued at five times more than ABcann will be during its IPO.
This is the most perfect wash, rinse, repeat model in the marijuana industry
5. ABcann’s ultimate goal is global dominance.
Aside from its technological achievements and massive
It will to be the first INTERNATIONAL company to have advanced, high-quality marijuana products available on multiple continents.
From its home just across the U.S. border in Ontario, ABcann plans to expand in Canada to Saskatchewan and British Columbia.
It is in final stages of competition for a license in Hawaii…
It’s already supplying research-grade marijuana to an Israeli pharmaceutical company…
And it’s working on prospects in Australia and Germany.
6. Backed by essential
A successful marijuana company needs expertise in pharmaceuticals, agriculture and specialized medical marijuana science.
ABcann has it all.
ABcann has the right people in the right placeWe don’t usually fawn over company bios—because the business should speak for itself. But with in this new Marijuana Space, reputation is indispensable, and experience is priceless.
ABcann's management and advisors include:
Marijuana Science Experience
Raphael Mechoulam, PhD - known as “The Father of Medical Marijuana” is an organic chemist and professor of Medicinal Chemistry at the Hebrew University of Jerusalem.
He is the first scientist to isolate cannabidiol sdff (CBD) in 1963 and first scientist to isolate tetrahydrocannabinol (THC).
Mechoulam has also won over 25 academic awards including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.
Agriculture Science Experience
Mike Dixon, PhD - Professor, School of Environmental Sciences, Director of the Controlled Environment Systems Research Facility, University of Guelph.
He formed the Space and Advanced Life Support Agriculture (SALSA) program.
Dixon also leads the world in technology developments and research dedicated to studying plant and microbial interactions in advanced life support systems.
Paul Lucas - Is former President and CEO of GlaxoSmithKline Canada for 18 years.
He was also the former Chairman for TM Bioscience, Director for Biochem Pharma, the Toronto Regional Research Alliance, Montreal inVivo, and AllerGen. Lucas is currently a Director of the Ontario Genomics Institute, consultant with Queen's University, an advisor to Lumira Capital and RnA Diagnostics, and Chair of Life Sciences Ontario.
It’s not often you get to see a great company...
In an industry set to grow 50%+ a year for years to come...
In a position where government is actually stifling new entrants...
With a proven technological edge years ahead of competitors…
Backed by multiple industry heavyweights...
And at a valuation which is a fraction of it’s competitors.
This is one of those times.
And you get to see it right when it first opens to the public.
Consider buying ABCann Global (TSX.V ABCN) today.